Metropolis Healthcare Share Price

Metropolis Healthcare reported a strong Q4 with significant growth in revenue, patient volumes, and profitability, driven by a shift towards specialized and preventive diagnostics. The company anticipates a steady medium-term growth of 14-15% CAGR, supported by successful integration of acquisitions and operational efficiencies.

• Economic Times
• 1 week 6 days ago

Healthcare Services company Metropolis Healthcare announced Q4FY26 & FY26 results Consolidated Financial Highlights: Revenue from operations for Q4FY26 stood at Rs 42,468.16 lakh, reflecting a YoY growth of 23.0% compared to Rs 34,529.15 lakh in Q4FY25 and a QoQ increase of 4.6% from Rs 40,590.97 lakh in Q3FY26. Total Income for Q4FY26 was Rs 43,284.31 lakh, as against Rs 35,226.23 lakh in Q4FY25 (up 22.9% YoY) and Rs 41,492.52 lakh in Q3FY26 (up 4.3% QoQ). Profit before tax (after exceptional items) for the quarter was Rs 6,976.26 lakh, marking a significant growth of 93.5% YoY from Rs 3,604.44 lakh in Q4FY25 and an increase of 22.1% QoQ from Rs 5,715.69 lakh in Q3FY26. Profit for the period reached Rs 5,095.95 lakh in Q4FY26, growing by 74.3% YoY compared to Rs 2,923.13 lakh in Q4FY25 and by 21.1% QoQ from Rs 4,208.71 lakh in Q3FY26. For the full year ended March 31, 2026, Revenue from operations was Rs 1,64,584.59 lakh, compared to Rs 1,33,120.28 lakh in FY25, representing an increase of 23.6%. Annual Profit for the period (Net Profit) for FY26 stood at Rs 19,118.20 lakh, showing a growth of 31.4% over Rs 14,551.39 lakh in FY25. Basic and Diluted Earnings Per Share (EPS) for continuing operations for Q4FY26 was Rs 2.46, compared to Rs 1.42 in Q4FY25. For FY26, the Basic EPS was Rs 9.19. The Board of Directors declared a 2nd Interim Dividend of Rs 1/- per equity share for the financial year 2025-26. Standalone Financial Highlights: Revenue from operations for Q4FY26 reached Rs 35,203.12 lakh, an increase of 12.9% YoY from Rs 31,168.61 lakh and 5.2% QoQ from Rs 33,471.38 lakh. Total Income for the quarter was Rs 36,084.79 lakh, up 13.0% YoY from Rs 31,928.18 lakh and 7.1% QoQ from Rs 33,692.96 lakh. Profit before tax (after exceptional items) for Q4FY26 was Rs 5,961.21 lakh, reflecting a substantial increase of 109.8% YoY from Rs 2,841.50 lakh and an increase of 40.9% QoQ from Rs 4,231.82 lakh. Profit for the period (Net Profit) for Q4FY26 stood at Rs 4,323.62 lakh, showing a growth of 81.3% YoY compared to Rs 2,385.06 lakh and 35.0% QoQ from Rs 3,203.27 lakh. For FY26, Standalone Revenue from operations was Rs 1,36,547.17 lakh, compared to Rs 1,21,575.19 lakh in FY25. Standalone Net Profit for FY26 was Rs 15,748.33 lakh, as against Rs 12,479.60 lakh in FY25. Business Highlights: Segment Performance: Based on the nature of the business and line of products/services, the company operates in only one reportable segment, which is Pathology service. Bonus Issue: The Company issued and allotted 15,54,95,826 bonus equity shares in the ratio of 3:1 (three new fully paid-up equity shares for every one existing fully paid-up equity share) during the year. Business Acquisitions: Acquisition of the entire business of Dr. Ahujas Pathology & Imaging Centre (DAPIC) was consummated on May 23, 2025, for a purchase consideration of Rs 3,461.00 lakh. Acquisition of the business of Dr. Ashok Kumar Sharma's Scientific Pathology was consummated on June 16, 2025, for a purchase consideration of Rs 6,450.00 lakh. Acquisition of pathology laboratories located in Kolhapur, Maharashtra, was completed on September 18, 2025, for a total purchase consideration of Rs 1,700.00 lakh. Asset Sale: During Q4FY26, a subsidiary completed the sale of its immovable property at Vashi, Navi Mumbai, resulting in a gain of Rs 648 lakh. Exceptional Items: For FY26, the company recognized exceptional items amounting to Rs 18,459 million (Consolidated) and Rs 18,463 million (Standalone), which includes profit from the slump sale of the Powder Coatings and International Research Center divisions, impact of new Labour Codes, and retention incentives. Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare, said: “The diagnostics industry in India is evolving towards more organised and science-led platforms, driven by increasing focus on trust, accuracy and clinical excellence. At Metropolis, our focus on scientific excellence, strong doctor relationships and advanced diagnostics positions us well in this evolving healthcare landscape. In Q4FY26, Metropolis delivered robust growth, with revenue increasing 23% YoY, while expanding our network beyond 5,000 centres across India. With healthcare increasingly moving towards preventive and personalised care, we remain committed to building a differentiated diagnostics platform driven by quality, innovation and customer trust.” Surendran Chemmenkotil, Managing Director, Metropolis Healthcare, said: “FY26 was an important year from an execution and operating transformation standpoint for Metropolis. Growth during the year was driven by healthy patient volumes, improved mix and stronger realisations, without any price increase in Q4, reflecting the strength of the underlying demand environment. We also made steady progress in productivity, network utilisation, lab optimisation and acquisition integration, supporting operating leverage and meaningful margin expansion. Going forward, we remain focused on driving sustainable growth, improving network throughput and delivering further efficiency-led margin expansion over the medium term.” Result PDF

• Trendlyne
• 1 week 6 days ago

Conference Call with Metropolis Healthcare Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 1 week 6 days ago